STOCK TITAN

Sera Prognostics Inc - SERA STOCK NEWS

Welcome to our dedicated news page for Sera Prognostics (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sera Prognostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sera Prognostics's position in the market.

Rhea-AI Summary
Sera Prognostics Inc. (SERA) announced financial results for Q4 and full year 2023, highlighting the positive recommendation to stop enrollment in their PRIME study due to efficacy. The company is preparing to publish study results and launch new products to enhance revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
-
Rhea-AI Summary
Sera Prognostics Inc. (NASDAQ: SERA) will report Q4 and full year 2023 financial results on March 20, 2024. The company focuses on pregnancy biomarker information for maternal and neonatal health. A conference call will discuss operational highlights and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
Rhea-AI Summary
Sera Prognostics Inc. (NASDAQ: SERA) will present at the TD Cowen 44th Annual Healthcare Conference to discuss its latest achievements in improving maternal and neonatal health through innovative pregnancy biomarker information. Zhenya Lindgardt, President and CEO, will provide a company update in a fireside chat on March 4, 2024, at 2:50 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences
Rhea-AI Summary
Sera Prognostics Inc. (Nasdaq: SERA) announced that the DSMB recommended stopping enrollment for its PRIME study due to efficacy, with both co-primary endpoints meeting stopping criteria for statistical significance at the pre-planned interim analysis. The company will focus on analyzing and reporting available data, with President and CEO Zhenya Lindgardt expressing excitement over the report of efficacy from the DSMB.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
161.43%
Tags
-
Rhea-AI Summary
Sera Prognostics Inc. (SERA) will present at the 35th Annual Piper Sandler Healthcare Conference on November 28, 2023. Doug Fisher, Sera's Chief Business Officer, will participate in a presentation at 10:50 a.m. ET. The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
conferences
-
Rhea-AI Summary
Sera Prognostics Inc. (SERA) announced financial results for Q3 2023, highlighting cost reduction activities, care coordination offering, and positive clinical trial findings. The company reported $42,000 in revenue, with total operating expenses of $8.2 million and a net loss of $7.2 million. Sera Prognostics had cash, cash equivalents, and available-for-sale securities of approximately $85.0 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.61%
Tags
Rhea-AI Summary
Sera Prognostics Inc. will report Q3 FY2023 financial results on November 8, 2023, after the market close. The company will host a conference call and webcast to discuss operational highlights and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
-
Rhea-AI Summary
Sera Prognostics Inc. to present at Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
Sera Prognostics Inc

Nasdaq:SERA

SERA Rankings

SERA Stock Data

313.23M
16.99M
18.11%
63.43%
0.61%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States
Salt Lake City

About SERA

sera prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications. sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. the company has assembled a strong management team and board of directors with significant clinical development and women’s healthcare diagnostic experience. the company is supported by a strong group of investors, including the bill & melinda gates foundation, chione, ltd, domain associates, interwest partners, catalyst health ventures, upstart life sciences capital, and osage university partners. the company is working with the bill & melinda gates foundation to translate its discoveries and develop technologies to benefit women and infants in underserved countries worldwide. sera prognostics is located in salt lake city, utah. sera launched its first diagnos